New H5N1 vaccine protects calves in tests

Bird-flu vaccines for cattle have been more of an idea than a tool. That is the gap this new study is trying to close. A team at the University of Nebraska–Lincoln says it built an H5N1 vaccine that worked in both mice and dairy calves, and the interesting part is not just that it raised antibodies — it also aimed immune protection at the nose and airways, where flu often gets started. The paper appeared in *npj Vaccines* on April 21, 2026, and it lands in the middle of a still-unfinished H5N1 problem in U.S. dairy herds. ### What did they actually make? This is a vectored vaccine — basically, a harmless adenovirus is used as the delivery vehicle for an H5 flu antigen. The Nebraska group used a “centralized consensus” H5 design, which means they tried to build one antigen sitting near the middle of many H5 family-tree branches instead of matching only one exact strain. They also switched adenovirus serotypes between prime and boost, a trick meant to keep the immune ### Why give it two ways? Because flu is a mucosal infection first and a body-wide infection second. An intramuscular shot is good at building blood antibodies and broader systemic immunity. An intranasal dose can do something the shot alone often does poorly — put immune defenses right in the respiratory tract. The team’s whole pitch is that you want both: protection against severe disease inside the animal, and protection at the entry point that could cut transmission between animals. ### What happened in the mice? The mouse data are the cleanest efficacy result in the paper. Vaccinated mice developed strong humoral and cellular responses, then were fully protected against lethal challenge from multiple divergent H5N1 strains. One of those was A/bovine/Ohio/B24OSU-439/2024 — a cattle-linked strain, which matters because this is supposed to be a livestock vaccine, not just another bird-flu proof of concept. the calves? The calves were vaccinated at 1 week of age and boosted 4 weeks later. In calves, the paper and the university summary emphasize strong immune responses rather than a direct calf challenge result like the mouse experiment. That distinction matters. The calf data support the idea that the platform translates into cattle biology, but they are still preclinical immunogenicity data, not the same thing as a large real-world field trial in dairy herds. ### Why does “consensus” matter here? Because H5N1 keeps changing. A strain-matched vaccine can work well, but it can also age badly if the virus drifts. A consensus antigen is an attempt to build something broader — not perfect for every branch, but decent across many of them. Think of it less like a custom key for one lock and more like a master key that opens enough doors to be useful on a farm. is still no licensed H5N1 vaccine for cattle in the United States. That is the real bottleneck. Even beyond the science, cattle vaccination runs into practical problems — challenge studies are hard, biosecurity rules are strict, and export markets worry that vaccination can complicate surveillance and trade. ### Why are protecting milk output. If vaccination lowers infection in cattle, it could also lower exposure for farm workers and reduce the number of chances the virus gets to adapt to mammals. The outbreak in dairy cattle started in early 2024, and researchers are still trying to answer a basic question: where does protection matter most — the respiratory tract, to hedge on both. ### Bottom line? This is promising, but it is still an early-stage farm vaccine story. The Nebraska team showed a smart design, strong calf immune responses, and full protection in mouse challenge tests. The next hurdle is the hard one — proving that this can work safely, at scale, in actual cattle operations where H5N1 is already a moving